Novocure's new system aims to make Optune therapy even easier for glioblastoma patients. Actor portrayal. (Photo: Business Wire) Novocure's second generation Optune system, at right, features a Tumor ...
The FDA has approved a lighter and more convenient version of the tumor-treating field device Optune for patients with glioblastoma multiforme. The FDA has approved a lighter and more convenient ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
The approval was based on findings from the phase 3 EF-14 trial. The FDA has expanded the indication for Optune (NovoTTF-100A System) in combination with Temodar (temozolomide) as a treatment for ...
St. Helier, NJ's Novocure ($NVCR) submitted a PMA supplement with the FDA, in hopes of marketing an upgraded version of its noninvasive Optune system to treat ...
SHREVEPORT, La. (Press Release) - Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results